EXL 01
Alternative Names: EXL-01Latest Information Update: 24 Oct 2024
At a glance
- Originator Exeliom Biosciences
- Class Anti-inflammatories; Antibacterials; Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators; Interleukin 10 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Clostridium difficile infections
- Phase I Crohn's disease
- Preclinical Gastric cancer; Liver cancer; Non-small cell lung cancer; Ulcerative colitis
Most Recent Events
- 02 Oct 2024 Exeliom Biosciences terminates the phase-I MAINTAIN trial in Crohn's disease in Belgium and Poland due to low recruitment (PO), (NCT05542355)
- 07 Jun 2024 Exeliom Biosciences plans a phase I/II trial for Non small cell lung cancer (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater, Combination therapy) (PO) in September 2024 (NCT06448572)
- 07 May 2024 Phase-I/II clinical trials in Clostridium difficile infections in France (PO) (NCT06306014) (EudraCT2023-506232-32-00)